Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Yared

Showing results (51-60 of 123) with videos related to

Pageof 13
Sort By:
The British Journal of Ophthalmology|February 11, 2022
Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and reviewAisha A Mumtaz, Andrew Fischer, Forat Lutfi, et al.
Blood Advances|December 23, 2021
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapySaurabh Dahiya, Tim Luetkens, Forat Lutfi, et al.
Blood|July 18, 2025
RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCTZachariah DeFilipp, Hannah K Choe, Yvonne A Efebera, et al.
Cytotherapy|February 10, 2024
A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell productsDjordje Atanackovic, Thierry Iraguha, Destiny Omili, et al.
Acta Haematologica|August 27, 2024
Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell TransplantationGabriela Sanchez-Petitto, Olga Goloubeva, James Childress, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 2, 2024
Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trialRawad A Yared, Chieh-Chang Chen, Astrid Vandorpe, et al.
British Journal of Haematology|March 4, 2020
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic MicroangiopathyNarendranath Epperla, Ang Li, Brent Logan, et al.
Neuro-Oncology|August 5, 2020
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomesNoa G Holtzman, Hao Xie, Soren Bentzen, et al.
Human Vaccines & Immunotherapeutics|June 6, 2023
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)Kathryn Kline, Wengen Chen, Michael E Kallen, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2024
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cellsKathryn Kline, Tim Luetkens, Rima Koka, et al.
Pageof 13

Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
The British Journal of Ophthalmology|February 11, 2022
Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and reviewAisha A Mumtaz, Andrew Fischer, Forat Lutfi, et al.
Blood Advances|December 23, 2021
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapySaurabh Dahiya, Tim Luetkens, Forat Lutfi, et al.
Blood|July 18, 2025
RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCTZachariah DeFilipp, Hannah K Choe, Yvonne A Efebera, et al.
Cytotherapy|February 10, 2024
A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell productsDjordje Atanackovic, Thierry Iraguha, Destiny Omili, et al.
Acta Haematologica|August 27, 2024
Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell TransplantationGabriela Sanchez-Petitto, Olga Goloubeva, James Childress, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 2, 2024
Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trialRawad A Yared, Chieh-Chang Chen, Astrid Vandorpe, et al.
British Journal of Haematology|March 4, 2020
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic MicroangiopathyNarendranath Epperla, Ang Li, Brent Logan, et al.
Neuro-Oncology|August 5, 2020
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomesNoa G Holtzman, Hao Xie, Soren Bentzen, et al.
Human Vaccines & Immunotherapeutics|June 6, 2023
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)Kathryn Kline, Wengen Chen, Michael E Kallen, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2024
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cellsKathryn Kline, Tim Luetkens, Rima Koka, et al.
Pageof 13